Epidermal growth factor receptor inhibitors (EGFRIs) are an increasingly important class of anticancer agents. Cutaneous toxicities, the most common adverse effects of EGFRI therapy, require dose modification or treatment cessation when moderate or severe and may compromise treatment compliance. To date, assessment has focused on physical symptoms associated with cutaneous toxicities; however, the psychosocial impact of those effects requires greater consideration. This article reviews current knowledge of assessment of cutaneous toxicities and identifies gaps in evidence, with particular focus on the psychosocial impact of cutaneous toxicities. Promising new assessment tools and approaches including the use of electronic patient-reported outcome measures are discussed, as well as implications for research in evaluating psychosocial interventions. (Boone et al., 2007; Hu, Sadeghi, PinterBrown, Yashar, & Chiu, 2007) . Drugs in the EGFRI class include the monoclonal antibodies cetuximab and panitumumab, as well as the tyrosine kinase inhibitors erlotinib, gefitinib, and lapatinib (Lynch et al., 2007) . To date, the drugs are used for a range of tumors, including lung, pancreatic, breast, head and neck, and colorectal cancers (Lynch et al., 2007) . Research in EGFRI therapies has increased because the agents have demonstrated efficacy and more clinically acceptable toxicity profiles compared to other treatment options in clinical trials (Lacouture & Melosky, 2007) . Interest also is significant in the potential clinical benefits of EGFRI and chemotherapy combination treatment (Perez-Soler, 2007) . As a result, this article will explore the challenges in comprehensively assessing cutaneous toxicities associated with EGFRIs and make recommendations for further research.
Although EGFRIs have a more acceptable toxicity profile compared to other anticancer therapies (e.g., chemotherapy), adverse treatment effects unique to EGFRIs have been identified. The toxicities primarily are cutaneous, particularly papulopustular eruption, and have been described as "acneform" (Segaert This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.
